Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc is experiencing positive momentum, evidenced by its emerging role in personalized cancer treatment through genomic sequencing and analytics, underscoring the efficacy of its NeXT Personal solutions. The clinical data highlights a significant correlation between minimal residual disease (MRD) status and improved patient outcomes, showcasing the utility of Personalis's technology in monitoring treatment responses and enhancing prognostic capabilities. Furthermore, advancements such as the reimbursement application for lung cancer diagnostics, based on the favorable findings from the NeoADAURA study, position the company favorably for future revenue growth and market expansion.

Bears say

Personalis Inc has faced significant challenges in its financial performance, leading to declining revenues in recent quarters, which raise concerns about the sustainability of its growth trajectory. The company’s reliance on its sole segment of sequencing and data analysis services exposes it to market volatility and competitive pressures within the rapidly evolving biotechnology sector. Additionally, increased operational costs and investment requirements for research and development may further strain profitability, casting doubt on its ability to achieve long-term financial stability.

Personalis Inc (PSNL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.